Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2017

Interventional Pharmacology: A Guideline-based Review

Presenter: Jose de Ribamar Costa Jr, Jose L. Leiva-Pons, Dominick J. Angiolillo

October 29, 2017

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Todd Neale

September 07, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Todd Neale

March 10, 2017

Presentation JIM 2017

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Presenter: Dominick J. Angiolillo

February 10, 2017

CME

Advertisement

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Interventional Pharmacology: A Guideline-based Review

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content